Pharmafile Logo

AstraZeneca and Merck decision to disinvest in the UK is a ‘tragedy’ for British research and innovation

Kate Shaw comments on the latest news about AstraZeneca and Merck’s decision to hold planned investments in the UK

- PMLiVE

The recent decision by pharmaceutical company AstraZeneca to pause a planned £200 million expansion of its Cambridge research site and the announcement by Merck (known as MSD in Europe) to withdraw its life science research operation from the UK have been described as a ‘tragedy’ by Innovative Trials’ founder and CEO, Kate Shaw.

 

Read more here: https://innovativetrials.com/astrazeneca-and-merck-decision-to-disinvest-in-uk-is-a-tragedy-for-british-research-and-innovation-says-innovative-trials/

This content was provided by Innovative Trials